Exelixis Inc. (EXEL)
Why Exelixis (EXEL) Might be Well Poised for a Surge
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Exelixis Earnings Drive Share Growth
Oncology company Exelixis, Inc. (EXEL) reported better-than-expected results, driving big share gains.
3 Stocks to Buy for a Soft Landing, If There Is One
Recent economic data is reigniting talk about a soft landing for the economy. That means that the Federal Reserve's monetary policy regarding interest rates is neither too restrictive nor too loose.
4 Best Defensive Stocks For A Potential Soft Landing (SA Quant)
Investors are seeking stability amid the global market selloff in early August, sparked by weak jobs data and fears of an emergency interest rate cut by the Fed. Recession fears were ignited after the yield curve uninverted to cause speculation that the Fed could begin rate cuts in September. With many investors on the defense, and seeking safe-haven investments, staples, healthcare, and utilities have outperformed the market during six of the last seven U.S. recessions.
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue Trends
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost
Exelixis, Inc. has a PDUFA date of April 3, 2025, set to decide whether Cabometyx should be approved for the treatment of patients with advanced pancreatic neuroendocrine tumors. U.S. net product revenues of Cabometyx grew by 16% quarter over quarter and a 7% year-over-year increase. Preliminary results from phase 3 STELLAR-303 study, using zanzalintinib in combination with Tecentriq to treat patients with metastatic refractory colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient.
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues
Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed.
Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer Amy Peterson - Executive Vice President, Product Development, Medical Affairs and Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - Executive Vice President of Commercial Conference Call Participants Asthika Goonewardene - Truist Jay Olson - Oppenheimer Joyce Zhou - TD Cowen Andy Hsieh - William Blair Silvan Tuerkcan - Citizens JMP David Lebowitz - Citi Michael Riad - Morgan Stanley Jason Gerberry - Bank of America Akash Tewari - Jefferies Alex Bullocks - Barclays Sudan Loganathan - Stephens Chris Shibutani - Goldman Sachs Operator Good day, ladies and gentlemen, and welcome to the Exelixis Second Quarter 2024 Financial Results Conference Call.
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
